Recent Finacing
Recent Raise
Cartherics develops allogeneic iPSC-derived CAR-NK and CAR-T immunotherapies from cord blood, genetically engineering safe-harbor sites to enhance NK/T cells; lead CTH-401 targets TAG-72 and advances to clinical trial.
Focus Areas
Total Raised
Funding round
See the team members at Cartherics.
